Legend Biotech Corp. (NASDAQ:LEGN), a global leader in cell therapy, reported its fourth quarter and full-year 2025 financial results, delivering a mixed performance against analyst expectations. The company's flagship product, CARVYKTI®, continued to demonstrate strong commercial momentum, though the bottom-line results and market reaction revealed a more nuanced picture.
Earnings and Revenue Versus Estimates
For the quarter ended December 31, 2025, Legend Biotech reported total revenue of $306.3 million, which fell short of the analyst consensus estimate of approximately $313.0 million. The revenue primarily consisted of collaboration revenue from its partnership with Janssen (Johnson & Johnson) related to CARVYKTI sales.
On a per-share basis, the company reported a net loss of $0.08. This result, however, surpassed the consensus estimate, which had anticipated a larger loss of $0.11 per share. The better-than-expected bottom-line figure was driven by improved operating performance and higher gross profit from CARVYKTI.
Key financial comparisons for Q4 2025:
- Reported Revenue: $306.3 million
- Estimated Revenue: ~$313.0 million
- Reported EPS (Net Loss): ($0.08)
- Estimated EPS (Net Loss): ($0.11)
The company also reported that CARVYKTI achieved franchise profitability for the full year 2025, a significant operational milestone.
Market Reaction and Price Action
The immediate market reaction to the earnings release appears cautiously positive. In pre-market trading following the announcement, Legend Biotech's stock showed an increase of approximately 0.78%. This upward move suggests investors may be focusing on the earnings beat and the continued strong commercial story for CARVYKTI, rather than the slight revenue miss.
This pre-market gain builds on a positive monthly trend, with the stock up about 11.9% over the last month. However, performance has been more muted over shorter periods, with a 3.8% gain in the last week and a slight decline of 3.1% over the prior two weeks, indicating some volatility leading into the earnings report.
Key Business Highlights from the Report
Beyond the financial figures, the earnings release underscored several important operational achievements for Legend Biotech:
- CARVYKTI Commercial Strength: Net trade sales for CARVYKTI were approximately $555 million in Q4 and $1.9 billion for the full year 2025. The company has now treated over 10,000 patients globally.
- Manufacturing and Commercial Expansion: The company completed the expansion of its Raritan, NJ facility, now the largest cell therapy manufacturing site in the U.S. CARVYKTI is available at 294 sites across 14 markets.
- Pipeline Advancement: Early-stage programs progressed, including the first-patient dosing for in vivo candidates and the presentation of first-in-human results for LUCAR-G39D, an allogeneic CAR-T therapy.
- Strong Balance Sheet: The company ended the year with approximately $949 million in cash, cash equivalents, and time deposits, providing a financial runway it believes extends beyond 2026.
Forward-Looking Commentary and Estimates
While the press release did not provide specific quantitative financial guidance for 2026, management expressed confidence in its path, stating it believes the company will achieve a company-wide operating profit in 2026.
Analysts currently project full-year 2026 sales for Legend Biotech to reach approximately $1.51 billion. For the upcoming first quarter of 2026, the consensus sales estimate stands at about $316.4 million, with an expected loss per share of $0.07.
For a detailed view of historical earnings and future analyst projections, you can review the earnings history and analyst estimates for Legend Biotech.
Conclusion
Legend Biotech's Q4 2025 results paint a picture of a company in transition, successfully scaling its first commercial product to profitability while investing heavily in its next generation of therapies. The earnings beat, coupled with strong commercial execution for CARVYKTI, appears to have resonated positively with investors in early trading. The focus now shifts to the company's ability to maintain its commercial momentum, achieve its target of company-wide operating profit in 2026, and advance its promising pipeline to build a sustainable, multi-product cell therapy leader.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
